基于主要组织相容性复合体II类的中风治疗方法。
Major histocompatibility complex Class II-based therapy for stroke.
作者信息
Gonzales-Portillo Bella M, Lee Jea-Young, Vandenbark Arthur A, Offner Halina, Borlongan Cesario V
机构信息
Department of Biomedical Engineering, Northwestern University, Evanston, IL, USA.
Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
出版信息
Brain Circ. 2021 Mar 30;7(1):37-40. doi: 10.4103/bc.bc_16_21. eCollection 2021 Jan-Mar.
This review discusses the potential of major histocompatibility complex (MHC) Class II constructs as stroke therapeutics. We focus on the delivery of MHC Class II construct, DRmQ, as a safe and effective treatment for ischemic stroke. DRmQ was observed to attenuate behavioral deficits and decrease microglia activation and proinflammatory cytokines, illustrating its ability to mitigate the secondary cell death following stroke. Similar anti-neuroinflammation treatments, such as transplantation of mesenchymal stem cells and mitochondrial transfers, are briefly discussed to provide further support that sequestration of inflammation stands as a robust therapeutic target for stroke.
本综述讨论了主要组织相容性复合体（MHC）II类构建体作为中风治疗方法的潜力。我们重点关注MHC II类构建体DRmQ的递送，它是一种用于缺血性中风的安全有效的治疗方法。观察到DRmQ可减轻行为缺陷，减少小胶质细胞活化和促炎细胞因子，表明其具有减轻中风后继发性细胞死亡的能力。还简要讨论了类似的抗神经炎症治疗方法，如间充质干细胞移植和线粒体转移，以进一步支持炎症隔离作为中风的有力治疗靶点。
Zotero 插件